OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

All Filters

Clear
Clear
Clear
Clear
Clear
Clear
Clear
Investigator: Glenn Larsen

1 Projects | 1 Researchers | $2,999,586 Invested

2024

Aquinnah Pharmaceuticals

Glenn Larsen, PhD

Development of Orally Available, Brain Penetrant Compound Reducing Tau Pathology.

  • Funding Amount: $2,999,586
  • Organization Type: Biotechnology/For Profit
  • Program: Drug Discovery
  • Target: Tau
  • Status: Active